SEC Comment Letter for ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Sep 29, 2017
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Sept. 29, 2017 · CIK: 0001612940 · Accession: 0000000000-17-034711
AI Filing Summary & Sentiment
Letter
September 29, 2017 Smital Shah Chief Financial Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands ProQR Therapeutics N.V. Form 20-F for Fiscal Year Ended December 31, 2016 Filed March 31, 2017 File No. 001-36622Re: Dear Ms. Shah: We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 20-F for year ended December 31, 2016 Intellectual Property, page 56 1. In future filings, please expand your discussion regarding your exclusive license agreement with the Radboud University with respect to your LCA program to disclose the material terms, including the term, royalty term, and termination provisions of the agreement, as well as the royalty and other material payment provisions. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Smital Shah ProQR Therapeutics N.V. September 29, 2017 Page 2 Please contact Jeffrey Gabor at 202-551-2544 or Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
September 29, 2017 Smital Shah Chief Financial Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands ProQR Therapeutics N.V. Form 20-F for Fiscal Year Ended December 31, 2016 Filed March 31, 2017 File No. 001-36622Re: Dear Ms. Shah: We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 20-F for year ended December 31, 2016 Intellectual Property, page 56 1. In future filings, please expand your discussion regarding your exclusive license agreement with the Radboud University with respect to your LCA program to disclose the material terms, including the term, royalty term, and termination provisions of the agreement, as well as the royalty and other material payment provisions. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Smital Shah ProQR Therapeutics N.V. September 29, 2017 Page 2 Please contact Jeffrey Gabor at 202-551-2544 or Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance